Cingulate Inc. (CING) Dividend History

Company News

• Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

  Cingulate Inc. reported positive results for its lead ADHD asset CTx-1301, including successful completion of Phase 3 trials and plans to submit a New Drug Application in mid-2025. The company also strengthened its balance sheet through various financing activities.

  GlobeNewswire Inc.
• Cingulate Announces Adjournment of Special Meeting

  Cingulate Inc. has adjourned its Special Meeting of Stockholders to provide additional time for stockholders to vote on all proposals. The company's Board of Directors continues to believe that the proposals are in the best interests of the stockholders.

  GlobeNewswire Inc.
• Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

  Cingulate Inc. announced that it was issued a European patent for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent will cover up to 30 European territories, including the United Kingdom.

  GlobeNewswire Inc.
• Why WD-40 Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Benzinga

  WD-40 Company reported stronger-than-expected Q3 results, leading to a 12.5% jump in its stock price in pre-market trading. Several other stocks also saw significant price movements in the pre-market session.

  Benzinga

  Featured Companies: ASNS CTM IVP LGVN LUCY LVWR NEGG PSMT SPRC WDFC YGMZ
• Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

  KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the entry into definitive agreements for the immediate exercise of certain outstanding Series A warrants to purchase up to an aggregate of 2,125,000 shares of common stock of the Company and Series B warrants to purchase up to an aggregate of 1,062,500 shares of common stock of the Company originally issued in February 2023, having an exercise price of $2.00 per share, at a reduced exercise price of $0.585 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-276502). The offering is expected to close on or about July 1, 2024, subject to satisfaction of customary closing conditions.

  GlobeNewswire Inc.